9 May 2024 (Thursday) - Oncology Central Update

The nice people at Oncology Central sent their update today. Much of it floew over my head… some stuck though.

 

RNA-LPAs: the latest breakthrough in immuno-oncology?   From 'cold' to 'hot' in just 48 hours. Read about a novel mRNA vaccine technology, which rapidly reprograms the tumor microenvironment, triggering a robust immune response against cancer.

Poster highlights from AACR 2024 READ MORE >>>

Championing diversity and inclusion in neuro-oncology READ MORE >>>

ANKTIVA® receives US FDA approval for bladder cancer subtype READ MORE >>>

JOURNAL ARTICLES

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review Here the authors report on a case of a patient with a strictly third-ventricle papillary craniopharyngioma with a BRAF V600E mutation. After initial surgery with subtotal resection, the patient demonstrated durable response to targeted BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib, suggesting that targeted therapy may reduce the need for radiation and impact surgical interventions in select cases. MORE >>>

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience In this study, researchers retrospectively evaluated the effects of dabrafenib/trametinib combination in patients with BRAF-mutated NSCLC. They observed a longer, statistically significant median progression-free survival in patients receiving the combination in first-line vs those in the second/subsequent lines.  MORE >>>

LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma This study outlines the design and rationale for the randomized, open-label, Phase III LEAP-014 study of lenvatinib in combination with pembrolizumab plus chemotherapy in patients with advanced or metastatic ESCC. Overall survival and progression-free survival are the dual primary end points. MORE >>>